Novavax Investor Relations https://ir.novavax.com/ Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study https://novavax.investorroom.com/press-releases?item=610 <p>Sanofi presented positive results from COMPARE, the first head-to-head, double-blind, randomized Phase 4 study powered to directly compare the tolerability profiles of Novavax&rsquo;s protein-based non-mRNA COVID-19 vaccine Nuvaxovid&trade; and mNEXSPIKE, Moderna&#39;s latest mRNA COVID-19 vaccine. The study showed that Nuvaxovid demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE across all pre-specified endpoints.</p> 04/18/2026 https://novavax.investorroom.com/press-releases?item=610 Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP  https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP <p>Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices (ACIP) Meeting</p> 09/19/2025 https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP Novavax Statement on Publicly Available COVID-19 Vaccine Data https://novavax.investorroom.com/Novavax-Statement-on-Publicly-Available-COVID-19-Vaccine-Data <p>Novavax is a U.S.-based biotechnology company that is proud to have successfully developed a COVID-19 vaccine as part of President Trump’s Operation Warp Speed.</p> 09/03/2025 https://novavax.investorroom.com/Novavax-Statement-on-Publicly-Available-COVID-19-Vaccine-Data Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine https://novavax.investorroom.com/Latest-update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine-1 <p>Novavax has responded to the FDA regarding its Biologics License Application, addressing a postmarketing commitment request and expressing confidence in the approvability of its application pending final alignment.</p> 04/28/2025 https://novavax.investorroom.com/Latest-update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine-1 Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine https://novavax.investorroom.com/Latest-update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine <p>We believe our BLA is approvable and are working with the FDA to address a PMC request received post-PDUFA to move toward final approval.</p> 04/23/2025 https://novavax.investorroom.com/Latest-update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine